Daily Newsletter

13 November 2023

Daily Newsletter

13 November 2023

Telix and Mauna Kea join forces to expand cancer surgery innovation

Telix will acquire 19.33% of Mauna Kea’s ordinary shares in a reserved private placement, with the deal closing on 17 November 2023.

Jenna Philpott November 13 2023

Telix Pharmaceuticals and Mauna Kea Technologies are partnering to expand the Imaging and Robotics in Surgery (IRiS) Alliance, investing €6m ($6.4m) to develop hybrid pharmaceutical-device products.  

The collaboration combines Telix’s cancer-targeting agents with Mauna Kea’s Cellvizio surgical endomicroscopy platform, which offers real-time visualisation of cancer tissues during surgery. 

As part of the deal, Telix will purchase 11,911,852 new ordinary shares at a price of €0.5037 ($0.54) per share. After the deal closes on 17 November 2023, Telix will own 19.33% of the share capital and 19.01% of the voting rights.  

Australian company Telix said the strategic investment is synergistic with its recent acquisitions of Lightpoint and Dedicaid. 

Telix and Mauna Kea initially joined forces for the IRiS Alliance in December 2020, in a bid to develop advanced image-guided surgical technologies in the field of urologic oncology.  

GlobalData’s Medical Intelligence Centre shows that Telix has eight products in the pipeline. Its marketed product, Illucix (TLX591-CDx), gained approval from the US Food and Drug Administration (FDA) in December 2021. The therapy is a radiopharmaceutical imaging agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) in patients with prostate cancer.  

In November, Telix announced a deal with Danish company Wiik Pharma for the distribution of Illuccix, one of its radiopharmaceutical imaging agents, in the Nordics. The deal will see Wiik Pharma as the company’s sole distributor across Denmark, Finland, Norway, and Sweden for a period of three years from the national approved date in each country.  

Managing director and group CEO of Telix, Christian Behrenbruch, said: “We are committed to expanding this partnership, which brings together the cutting-edge technologies in targeted radiation, radio-guided surgery and real-time in vivo cellular imaging our respective companies are developing.” 

The aging population is a captive market for medical devices

With rising pressure on governments, payers, and manufacturers to reduce healthcare costs, innovative medical technologies have tremendous potential to improve elder care. Advancements in medical device technology have resulted in a significant increase in the number of conditions that can be managed in a home care setting. To capitalize on this strong demand and growth, manufacturers are increasingly producing consumer-targeted equipment.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close